NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.

Although the increase did not reach statistical significance, NT-I7 treatment tended to induce a higher GZMB level compared to the rhIL-7 and control groups (Fig. 7 D).

also in 111,027 other papers